摘要
目的观察阿帕替尼联合多西他赛二线以上治疗对晚期非小细胞肺癌(NSCLC)患者CEA、SCC及CA125的影响。方法将62例晚期NSCLC患者随机分为观察组及对照组,每组31例。对照组给予多西他赛治疗,观察组在此基础上另给予阿帕替尼。治疗后,观察2组患者的近期疗效。治疗前后,对2组患者的生活质量进行评价,主要项目包括情绪功能、躯体功能、社会功能、认知功能及角色功能。治疗前后,分别检测两组肿瘤标记物含量,主要项目包括癌胚抗原(CEA)、鳞状上皮细胞癌抗原(SCC)及糖蛋白抗原125(CA125)。治疗期间,观察2组出现的毒副作用,主要项目包括过敏反应、心血管毒性、肝功能损伤、骨髓抑制、神经毒性及胃肠道反应等。结果治疗后观察组有效率及控制率均明显高于对照组(P <0. 05)。治疗后观察组情绪功能、躯体功能、社会功能、认知功能及角色功能评分均明显高于对照组(P <0. 05)。治疗后观察组CEA、SCC及CA125均明显高于对照组(P <0. 05)。治疗期间,两组过敏反应、心血管毒性、肝功能损伤、骨髓抑制、神经毒性及胃肠道反应的发生率均无明显差异(P> 0. 05)。结论阿帕替尼联合多西他赛二线以上治疗晚期NSCLC疗效较好,且可改善患者CEA、SCC及CA125水平。
Objective To study the effects of apatinib combined with docetaxel second line treatment of patients with advanced non-small cell lung cancer( NSCLC) on CEA,SCC and CA125. Methods 62 advanced NSCLC patients were randomly divided into the observation group and the control group,31 cases in each group. The control group was treated with docetaxel,while the observation group was given apatinib on the basis of the control group. After the treatment,the effects of the 2 groups were observed. Before and after treatment,the levels of tumor markers [CEA,SCC and CA125],life quality scores( emotional function,physical function,social function,cognitive function and role function) were observed in the 2 groups. During the treatment,the adverse effects of the 2 groups were closely observed,including allergic reactions,cardiovascular toxicity,liver function injury,bone marrow suppression,neurotoxicity and gastrointestinal reactions. Results After the treatment,the effective and remission rates of the observation group was significantly higher than the control group( P < 0. 05). After the treatment,the emotional function,physical function,social function,cognitive function and role function scores were significantly lower in the observation group than the control group( P < 0. 05),and the CEA,SCC and CA125 levels were significantly lower in the observation group than the control group( P < 0. 05). The rates of allergic reactions,cardiovascular toxicity,liver function injury,bone marrow suppression,neurotoxicity and gastrointestinal reactions were similar in the observation group than the control group( P > 0. 05). Conclusion The method of apatinib combined with docetaxel is effective in the treatment of advanced NSCLC and can improve the levels of CEA,SCC,CA12 in patients.
作者
尚可
胡若洋
胡继德
SHANG Ke;HU Ruoyang;HU Jide(Xinyang Central Hospital,Xinyang,464000)
出处
《实用癌症杂志》
2019年第7期1172-1175,共4页
The Practical Journal of Cancer
